IP Library › Granted Patent US 12,215,156
Granted Patent B2
US 12,215,156 · App. 18/494,007 · Granted Feb 4, 2025

HER-2 targeted bispecific compositions and methods for making and using the same

Inventors: Volker Schellenberger (Palo Alto, CA); Eric Johansen (Oakland, CA); Angela Henkensiefken (San Jose, CA); Darragh Maccann (Magherfelt, GB); James McClory (Banbridge, GB); Philipp Kuhn (Breman, DE); Andre Frenzel (Braunschweig, DE); Bryan Irving (Woodside, CA); Mika Derynck (South San Francisco, CA)
Assignee: Amunix Pharmaceuticals, Inc.
C07K16/2809A61P35/00C07K16/2818C07K16/2827C07K16/32C12N15/70C07K2317/31C07K2319/30C12N2800/101
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,156
App. No.
18/494,007
Granted
Feb 4, 2025
Kind
B2
Abstract

Disclosed herein are polypeptides, and methods of making and using such polypeptides, that comprise a bispecific antibody construct covalently linked to an extended recombinant polypeptide comprising a barcode fragment releasable from said polypeptide upon digestion by a protease, and a Release Segment that can be proteolytically cleaved wherein said cleavage releases the bispecific antibody construct from the extended recombinant polypeptide.

Claims (8)

1. A polypeptide comprising the amino acid sequence of SEQ ID NO: 34.

2. The polypeptide of claim 1 consisting of the amino acid sequence of SEQ ID NO: 34.

3. A pharmaceutical composition comprising a polypeptide of claim 1 and one or more pharmaceutically suitable excipients.

4. A method of treating a HER2-expressing cancer in a subject, wherein the cancer is a solid tumor, the method comprising administering to said subject one or more therapeutically effective doses of a pharmaceutical composition of claim 3 .

5. A nucleic acid comprising (a) a polynucleotide sequence encoding a polypeptide of claim 1 ; or (b) a reverse complement of said polynucleotide sequence of (a).

6. An expression vector comprising a polynucleotide sequence of claim 5 and a recombinant regulatory sequence operably linked to said polynucleotide sequence.

7. A host cell, comprising an expression vector of claim 6 .

8. The method of claim 4 , wherein the HER2-expressing cancer is selected from breast cancer, colorectal cancer, non-small cell lung cancer, and ovarian cancer.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2025
From: YUMAB GMBH
To: AMUNIX PHARMACEUTICALS, INC.
Reel/Frame 069736/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2025
From: FUSION ANTIBODIES PLC
To: AMUNIX PHARMACEUTICALS, INC.
Reel/Frame 069849/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2024
From: SCHELLENBERGER, VOLKER; JOHANSEN, ERIC; HENKENSIEFKEN, ANGELA; IRVING, BRYAN; DERYNCK, MIKA
To: AMUNIX PHARMACEUTICALS, INC.
Reel/Frame 067222/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2024
From: KUHN, PHILIPP; FRENZEL, ANDRE
To: YUMAB GMBH
Reel/Frame 067222/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2024
From: MACCANN, DARRAGH; MCCLORY, JAMES
To: FUSION ANTIBODIES, PLC
Reel/Frame 067222/0469 →
Continuity (8)
Continuation 18064253 · Dec 10, 2022
Continuation PCTUS2021039006 · Jun 24, 2021
Provisional Application 63196408 · Jun 3, 2021
Provisional Application 63166857 · Mar 26, 2021
Provisional Application 63108783 · Nov 2, 2020
Provisional Application 63077503 · Sep 11, 2020
Provisional Application 63044301 · Jun 25, 2020
Related Publication 20240076378A1 · Mar 7, 2024
References Cited (129)
US 3992518A · Chien et al. · 1976 [cited by applicant]
US 4088864A · Theeuwes et al. · 1978 [cited by applicant]
US 4200098A · Ayer et al. · 1980 [cited by applicant]
US 4284444A · Bernstein et al. · 1981 [cited by applicant]
US 4398908A · Siposs et al. · 1983 [cited by applicant]
US 4435173A · Siposs et al. · 1984 [cited by applicant]
US 4684479A · D'Arrigo et al. · 1987 [cited by applicant]
US 4861800A · Buyske et al. · 1989 [cited by applicant]
US 4933185A · Wheatley et al. · 1990 [cited by applicant]
US 4976696A · Sanderson et al. · 1990 [cited by applicant]
US 4988337A · Ito · 1991 [cited by applicant]
US 5017378A · Turner et al. · 1991 [cited by applicant]
US 5176502A · Sanderson et al. · 1993 [cited by applicant]
US 5186938A · Sablotsky et al. · 1993 [cited by applicant]
US 5215680A · D'Arrigo et al. · 1993 [cited by applicant]
US 5298022A · Bernardi · 1994 [cited by applicant]
US 5318540A · Athayde et al. · 1994 [cited by applicant]
US 5364934A · Drayna et al. · 1994 [cited by applicant]
US 5492534A · Athayde et al. · 1996 [cited by applicant]
US 5573776A · Harrison et al. · 1996 [cited by applicant]
US 5660848A · Moo-Young et al. · 1997 [cited by applicant]
US 5756115A · Moo-Young et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5874104A · Adler-Moore et al. · 1999 [cited by applicant]
US 5885573A · Bluestone et al. · 1999 [cited by applicant]
US 5916588A · Popescu et al. · 1999 [cited by applicant]
US 5965156A · Proffitt et al. · 1999 [cited by applicant]
US 6043094A · Martin et al. · 2000 [cited by applicant]
US 6056973A · Allen et al. · 2000 [cited by applicant]
US 6110498A · Rudnic et al. · 2000 [cited by applicant]
US 6126966A · Abra et al. · 2000 [cited by applicant]
US 6183770B1 · Muchin et al. · 2001 [cited by applicant]
US 6254573B1 · Haim et al. · 2001 [cited by applicant]
US 6284276B1 · Rudnic et al. · 2001 [cited by applicant]
US 6294191B1 · Meers et al. · 2001 [cited by applicant]
US 6294201B1 · Kettelhoit et al. · 2001 [cited by applicant]
US 6309370B1 · Haim et al. · 2001 [cited by applicant]
US 6316024B1 · Allen et al. · 2001 [cited by applicant]
US 6352716B1 · Janoff et al. · 2002 [cited by applicant]
US 6352721B1 · Faour · 2002 [cited by applicant]
US 6361796B1 · Rudnic et al. · 2002 [cited by applicant]
US 6406632B1 · Safir et al. · 2002 [cited by applicant]
US 6406713B1 · Janoff et al. · 2002 [cited by applicant]
US 6491916B1 · Bluestone et al. · 2002 [cited by applicant]
US 6514532B2 · Rudnic et al. · 2003 [cited by applicant]
US 6534090B2 · Puthli et al. · 2003 [cited by applicant]
US 6572585B2 · Choi · 2003 [cited by applicant]
US 6713086B2 · Qiu et al. · 2004 [cited by applicant]
US 6715485B1 · Djupesland · 2004 [cited by applicant]
US 6743211B1 · Prausnitz et al. · 2004 [cited by applicant]
US 6759057B1 · Weiner et al. · 2004 [cited by applicant]
US 6814979B2 · Rudnic et al. · 2004 [cited by applicant]
US 6838093B2 · Burnside et al. · 2005 [cited by applicant]
US 6890918B2 · Burnside et al. · 2005 [cited by applicant]
US 6945952B2 · Kwon · 2005 [cited by applicant]
US 7294513B2 · Wyatt · 2007 [cited by applicant]
US 8557961B2 · Silverman et al. · 2013 [cited by applicant]
US 9249211B2 · Schellenberger et al. · 2016 [cited by applicant]
US 9976166B2 · Schellenberger et al. · 2018 [cited by applicant]
US 10870874B2 · Schellenberger et al. · 2020 [cited by applicant]
US 11713358B2 · Schellenberger et al. · 2023 [cited by applicant]
US 20030228309A1 · Salcedo et al. · 2003 [cited by applicant]
US 20100239554A1 · Schellenberger et al. · 2010 [cited by applicant]
US 20100323956A1 · Schellenberger et al. · 2010 [cited by applicant]
US 20110046060A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110046061A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110077199A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110172146A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110288005A1 · Silverman et al. · 2011 [cited by applicant]
US 20120034228A1 · Schellenberger et al. · 2012 [cited by applicant]
US 20130165389A1 · Schellenberger et al. · 2013 [cited by applicant]
US 20170016042A1 · Schellenberger et al. · 2017 [cited by applicant]
US 20180346952A1 · Schellenberger et al. · 2018 [cited by applicant]
US 20190153115A1 · Schellenberger et al. · 2019 [cited by applicant]
US 20200385469A1 · Yang et al. · 2020 [cited by applicant]
US 20210164011A1 · Schellenberger et al. · 2021 [cited by applicant]
US 20230061715A1 · Schellenberger et al. · 2023 [cited by applicant]
US 20230121775A1 · Schellenberger et al. · 2023 [cited by applicant]
US 20230287040A1 · Schellenberger et al. · 2023 [cited by applicant]
US 20230295334A1 · Schellenberger et al. · 2023 [cited by applicant]
US 20230312729A1 · Schellenberger et al. · 2023 [cited by applicant]
US 20230322922A1 · Schellenberger et al. · 2023 [cited by applicant]
US 20240018260A1 · Schellenberger et al. · 2024 [cited by applicant]
WO WO1989009051A1 · 1989 [cited by applicant]
WO WO1998052976A1 · 1998 [cited by applicant]
WO WO2002079232A2 · 2002 [cited by applicant]
WO WO2005118635A2 · 2005 [cited by applicant]
WO WO2007033230A2 · 2007 [cited by applicant]
WO WO2010091122A1 · 2010 [cited by applicant]
WO WO2010144502A2 · 2010 [cited by applicant]
WO WO2010144508A1 · 2010 [cited by applicant]
WO WO2011028228A1 · 2011 [cited by applicant]
WO WO2011028229A1 · 2011 [cited by applicant]
WO WO2011028344A2 · 2011 [cited by applicant]
WO WO2011123813A2 · 2011 [cited by applicant]
WO WO2011123830A2 · 2011 [cited by applicant]
WO WO2014011819A2 · 2014 [cited by applicant]
WO WO2015023891A2 · 2015 [cited by applicant]
WO WO2016077505A2 · 2016 [cited by applicant]
WO WO2017040344A2 · 2017 [cited by applicant]
WO WO2019126576A1 · 2019 [cited by applicant]
WO WO2019160904A1 · 2019 [cited by applicant]
WO WO2020264200A1 · 2020 [cited by applicant]
WO WO2020264208A1 · 2020 [cited by applicant]
WO WO2021097186A1 · 2021 [cited by applicant]
Yan et al (Cancer Metastasis Research, 2015, vol. 34, pp. 157-164) (Year: 2015). [cited by examiner]
Podust et al (Journal of Controlled Release, 2016, vol. 240, pp. 52-66) (Year: 2016). [cited by examiner]
Hansen et al, Bioanalytics, e-pub Jul. 2018, 10 pages (Year: 2018). [cited by examiner]
Buchanan et al., “Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression,” mAbs, 2013, 5(2): 255-262. [cited by applicant]
Calceti et al., “Pharmacokinetic and biodistribution properties of polyethylene glycol)-protein conjugates,” Adv. Drug Deliv. Rev., 2003, 55: 1261-1277. [cited by applicant]
Cattaruzza et al., “Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors,” Nature Cancer, Mar. 30, 2023, 4: 485-501. [cited by applicant]
Datta-Mannan et al., “The interplay of non-specific binding, targetmediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies,” mAbs, Nov./Dec. 2015, 7(6): 1084-1093. [cited by applicant]
Hendricks et al., “Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect ,” Mol. Cancer Ther., Sep. 1, 2… [cited by applicant]
Herold et al., “Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus,” NEJM, May 30, 2002, 346: 1692-1698. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/US2021/039006, dated Nov. 1, 2021. [cited by applicant]
Li et al., “Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge,” mAbs, Sep./Oct. 2014, 6(5): 1255-1264. [cited by applicant]
Rawlings et al., “MEROPS: the peptidase database,” Nucleic Acids Res., 2008, 36(Suppl. 1): D320. [cited by applicant]
Shalaby et al., “Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene,” J. Exp. Med., 1992, 175: 217-225. [cited by applicant]
Stickler et al., “Human population-based identification of CD4+ T-cell peptide epitope determinants,” J Immunol Methods, 2003, 281(1-2): 95-108. [cited by applicant]
Sturniolo et al., “Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices,” Nat Biotechnol, 1999, 17: 555-561. [cited by applicant]
Tunnacliffe et al., “The majority of human CD3 epitopes are conferred by the epsilon chain,” Int. Immunol., 1989, 1(5): 546-550. [cited by applicant]
Van Zoelen et al., “The use of nonhomologous scatchard analysis in the evaluation of ligand-protein interactions,” Trends Pharmacol Sciences, 1998, 19(12): 487-490. [cited by applicant]
Cattaruzza et al., “HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On-Target, Off Tumor Toxicity and Provide Large Predicted Safety Margins in Non-Human Primates”, Amunix Pha… [cited by applicant]
Cattaruzza et al., “HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On-Target, Off Tumor Toxicity and Provide Large Predicted Safety Margins in Non-Human Primates”, Amunix Pha… [cited by applicant]
Cattaruzza et al., “HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On-Target, Off Tumor Toxicity and Provide Large Predicted Safety Margins in Non-Human Primates”, Amunix Pha… [cited by applicant]
Cattaruzza et al., “HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On-Target, Off Tumor Toxicity and Provide Large Predicted Safety Margins in Non-Human Primates”, Amunix Pha… [cited by applicant]
Cattaruzza et al., “HER2-XPAT, A Novel Protease-Activated Prodrug T Cell Engager (TCE) With Potent T Cell Activation and Efficacy in Solid Tumor Models and Large Predicted Safety Margins in Non-Human Primates”, Amunix P… [cited by applicant]
To et al., “AMX-818, a Protease-Activated T Cell Engager Targeting HER2 with Potent T Cell Activation, Proteolytic Cleavage and Efficacy in Xenograft Tumors, and Wide Safety Margins in Non-Human Primates”, AACR-NCI-EORT… [cited by applicant]
Egloff, et al. Engineered Peptide Barcodes for In-Depth Analyses of Binding Protein Ensembles. Nat Methods. Apr. 2, 20192; 16(5):421-428. [cited by applicant]